Skip to main
IBIO

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio Inc. is positioned positively within the biotechnology sector due to its innovative approach utilizing artificial intelligence to advance the development of precision antibodies. The company's technology significantly aims to reduce risks in downstream development, thereby enhancing the prospects for successful drug candidates and accelerating timelines. With a focus on optimizing manufacturability and subcutaneous administration of therapeutic candidates, iBio is strategically positioned to capitalize on market opportunities, especially as demand for effective treatments continues to grow.

Bears say

iBio Inc faces significant risks associated with the competitive landscape in biotechnology, as the development of new treatment methods may render its therapies obsolete or non-competitive. The outcomes of forthcoming phase I/II/III clinical studies for its therapeutic pipeline are uncertain, and failure to meet clinical endpoints could exert downward pressure on the company's shares. Furthermore, there are concerns regarding the company's ability to navigate regulatory scrutiny, as misinterpretations of preclinical and clinical trial data by authorities like the EMA and FDA could adversely affect its market position.

iBio (IBIO) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 4 analysts, iBio (IBIO) has a Buy consensus rating as of Apr 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.